Associate Fellow

Email:
spiegdoc@gmail.com
Education
B.A.
Yale University, 1971.
M.D.
University of Pennsylvania, 1975.

Description of BIOETHICS Expertise

ABOUT:
Robert J. Spiegel, M.D., FACP served as Chief Medical Officer and Senior Vice President, Schering-Plough Research Institute (SPRI) until end 2009. He served as medical liaison to the company’s global marketing units as well as to its business development function. Dr. Spiegel also chaired Schering-Plough's Safety Review Board (SRB) and Preparedness Response Process (PReP) and had direct responsibility for Global Pharmacovigilance.

Dr. Spiegel came to SPRI in 1983 as director, clinical research (oncology), and held positions of increasing managerial responsibility, including Vice President, Worldwide clinical research (all therapy areas). He was also a member of the company’s Strategic Licensing Board and Operations Management Team.

Dr. Spiegel earned his B.A. from Yale University and M.D. from the University of Pennsylvania. Following his residency in internal medicine he completed a fellowship in medical oncology at the National Cancer Institute, NIH. Before joining the pharmaceutical industry, Dr. Spiegel served as director of the Developmental Therapeutics Program at New York University Cancer Center and as assistant professor at New York University Medical Center (Department of Medicine). He served as adjunct assistant professor at NYU until 2005.

Dr. Spiegel has published over 70 scientific papers and serves on the Board of Directors of Cancer Care, Inc. and the Cancer Institute of New Jersey. He has special research interest in biological approaches to cancer therapy. He also has received numerous academic awards and fellowships, including the National Institutes of Health Biomedical Research Support Program Grant; Leukemia Society of America Special Fellowship; Mary Ellis Bell Prize of the University of Pennsylvania; and Student American Medical Association National Research Forum First Prize.

Dr. Spiegel now serves on the Boards of a number of biotechnology companies and is the founder and principle of Spiegel Consulting LLC. He is engaged formally and informally with Chief Medical Officers of Pharmaceutical and biotechnology companies and is particularly interested in issues of Conflict of Interest between biopharma, academia, and private/public entities.

SELECTED PUBLICATIONS

Spiegel RJ: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF): Clinical Review.
Hematopoietic Growth Factors, Ed. Peters WP, Futura Publ., 1990.

Dunton AW, Hanagan J, Zeffren J, Leavitt D, Spiegel RJ: Biological Therapy of Cancer.
New Jersey Medicine, Vol 87 (11 Spec No.), pp. 895-898, Nov. 1990.

Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappaport J, Ratain MJ,
Thompson J, Bonnem EM, Spiegel RJ, Tensen L, Burke JS, Vardiman JW. Survival
Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with
Interferon-Alpha 2b. Leukemia and Lymphoma, Vol. 4, pp. 99-102, 1991.

Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Harris J, Spiegel RJ, O'Connell MJ.
Complete Remission Induction with Combined VBMCP Chemotherapy and Interferon (rIFN
alpha-2b) in Patients with Multiple Myeloma. Leukemia & Lymphoma. Vol. 20, pp. 447-452,
1996.

Spiegel RJ: Reporting of Study Comparing Casodex, Eulexin (Letter), Onc News Report, 5, 15
1996.

The Pursuit Study Group. Inhibition of Platelet Glycoprotein IIb/IlIa with Eptifibatide in Patients
with Acute Coronary Syndromes without Persistent ST-Segment Elevation." N Eng J Med,
1998; 339:436-43.

Trotta PP, Antonelli G, Bausch J, Williams BRG, Spiegel RJ, von Wussow P. Approval
Standards for Alfa Interferon Subtypes. Drug Info J, Vol. 34, pp. 1231-1246, 2000.